33 results on '"Alapetite, Claire"'
Search Results
2. ESTRO-SIOPE guideline: Clinical management of radiotherapy in atypical teratoid/rhabdoid tumors (AT/RTs)
- Author
-
Timmermann, Beate, Alapetite, Claire, Dieckmann, Karin, Kortmann, Rolf-Dieter, Lassen-Ramshad, Yasmin, Maduro, John H., Ramos Albiac, Monica, Ricardi, Umberto, and Weber, Damien C.
- Published
- 2024
- Full Text
- View/download PDF
3. Brainstem toxicity after proton or photon therapy in children and young adults with localized intracranial ependymoma: A French retrospective study
- Author
-
Dalmasso, Céline, Alapetite, Claire, Bolle, Stéphanie, Goudjil, Farid, Lusque, Amélie, Desrousseaux, Jacques, Claude, Line, Doyen, Jérome, Bernier-Chastagner, Valérie, Ducassou, Anne, Sevely, Annick, Roques, Margaux, Tensaouti, Fatima, and Laprie, Anne
- Published
- 2024
- Full Text
- View/download PDF
4. The European Particle Therapy Network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation
- Author
-
De Roeck, Laurien, van der Weide, Hiska L., Eekers, Daniëlle B.P., Kramer, Miranda C., Alapetite, Claire, Blomstrand, Malin, Burnet, Neil G., Calugaru, Valentin, Coremans, Ida E.M., Di Perri, Dario, Harrabi, Semi, Iannalfi, Alberto, Klaver, Yvonne L.B., Langendijk, Johannes A., Méndez Romero, Alejandra, Paulsen, Frank, Roelofs, Erik, de Ruysscher, Dirk, Timmermann, Beate, Vitek, Pavel, Weber, Damien C., Whitfield, Gillian A., Nyström, Petra Witt, Zindler, Jaap, Troost, Esther G.C., and Lambrecht, Maarten
- Published
- 2022
- Full Text
- View/download PDF
5. Update of the EPTN atlas for CT- and MR-based contouring in Neuro-Oncology
- Author
-
Eekers, Daniëlle B.P., Di Perri, Dario, Roelofs, Erik, Postma, Alida, Dijkstra, Jeanette, Ajithkumar, Thankamma, Alapetite, Claire, Blomstrand, Malin, Burnet, Neil G, Calugaru, Valentin, Compter, Inge, Coremans, Ida E.M., Harrabi, Semi, Iannalfi, Alberto, Klaver, Yvonne L.B., Lambrecht, Maarten, Romero, Alejandra Méndez, Paulsen, Frank, Timmermann, Beate, Vitek, Pavel, van der Weide, Hiske L, Whitfield, Gillian A, Nyström, Petra Witt, Zindler, Jaap, de Ruysscher, Dirk, Langendijk, Johannes, Weber, Damien C, and Troost, Esther G.C.
- Published
- 2021
- Full Text
- View/download PDF
6. Patterns of proton therapy use in pediatric cancer management in 2016: An international survey
- Author
-
Journy, Neige, Indelicato, Daniel J., Withrow, Diana R., Akimoto, Tetsuo, Alapetite, Claire, Araya, Masayuki, Chang, Andrew, Chang, John Han-Chih, Chon, Brian, Confer, Michael E., Demizu, Yusuke, Dendale, Rémi, Doyen, Jérôme, Ermoian, Ralph, Gurtner, Kristin, Hill-Kayser, Christine, Iwata, Hiromitsu, Kim, Joo-Young, Kwok, Young, Laack, Nadia N., Lee, Choonsik, Lim, Do Hoon, Loredo, Lilia, Mangona, Victor S., Mansur, David B., Murakami, Masao, Murayama, Shigeyuki, Ogino, Takashi, Ondrová, Barbora, Parikh, Rahul R., Paulino, Arnold C., Perkins, Stephanie, Ramakrishna, Naren R., Richter, Ronald, Rombi, Barbara, Shibata, Satoshi, Shimizu, Shinichi, Timmermann, Beate, Vern-Gross, Tamara, Wang, Chiachien J., Weber, Damien C., Wilkinson, John Ben, Witt Nyström, Petra, Yock, Torunn I., Kleinerman, Ruth A., and Berrington de Gonzalez, Amy
- Published
- 2019
- Full Text
- View/download PDF
7. Long term outcome of skull-base chondrosarcoma patients treated with high-dose proton therapy with or without conventional radiation therapy
- Author
-
Weber, Damien C., Murray, Fritz, Combescure, Christophe, Calugaru, Valentin, Alapetite, Claire, Albertini, Francesca, Bolle, Stephanie, Goudjil, Farid, Pica, Alessia, Walser, Marc, Mammar, Hamid, Bachtiary, Barbara, Lomax, Tony, Noël, Georges, Dendale, Rémi, and Feuvret, Loic
- Published
- 2018
- Full Text
- View/download PDF
8. 849: Relapse Risk stratification in pediatric ependymoma patients using clinical data and radiomics
- Author
-
Tensaouti, Fatima, Blanchard, Nhi, Morisseau, Mathilde, Bolle, Stéphanie, Escande, Alexandre, Muracciole, Xavier, Alapetite, Claire, Claude, Line, Leseur, Julie, Doyen, Jérôme, Noël, Georges, Supiot, Stéphane, Bernier-Chastagner, Valérie, Welmant, Julien, Hatt, Mathieu, Bengoufa, Soumia, Figarella-Branger, Dominique, Varlet, Pascale, Uro-Coste, Emmanuelle, Gautier, Julien, Dalban, Cécile, Leblond, Pierre, and Laprie, Anne
- Published
- 2024
- Full Text
- View/download PDF
9. SIOPE – Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy
- Author
-
Ajithkumar, Thankamma, Horan, Gail, Padovani, Laetitia, Thorp, Nicky, Timmermann, Beate, Alapetite, Claire, Gandola, Lorenza, Ramos, Monica, Van Beek, Karen, Christiaens, Melissa, Lassen-Ramshad, Yasmin, Magelssen, Henriette, Nilsson, Kristina, Saran, Frank, Rombi, Barbara, Kortmann, Rolf, and Janssens, Geert O.
- Published
- 2018
- Full Text
- View/download PDF
10. Proton beam therapy for skull base chordomas in 106 patients: A dose adaptive radiation protocol
- Author
-
Fung, Vivien, Calugaru, Valentin, Bolle, Stéphanie, Mammar, Hamid, Alapetite, Claire, Maingon, Philippe, De Marzi, Ludovic, Froelich, Sébastien, Habrand, Jean-Louis, Dendale, Rémi, Noël, Georges, and Feuvret, Loïc
- Published
- 2018
- Full Text
- View/download PDF
11. Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus
- Author
-
Lambrecht, Maarten, Eekers, Daniëlle B.P., Alapetite, Claire, Burnet, Neil G., Calugaru, Valentin, Coremans, Ida E.M., Fossati, Piero, Høyer, Morten, Langendijk, Johannes A., Méndez Romero, Alejandra, Paulsen, Frank, Perpar, Ana, Renard, Laurette, de Ruysscher, Dirk, Timmermann, Beate, Vitek, Pavel, Weber, Damien C., van der Weide, Hiske L., Whitfield, Gillian A., Wiggenraad, Ruud, Roelofs, Erik, Nyström, Petra Witt, and Troost, Esther G.C.
- Published
- 2018
- Full Text
- View/download PDF
12. The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology
- Author
-
Eekers, Daniëlle BP, in 't Ven, Lieke, Roelofs, Erik, Postma, Alida, Alapetite, Claire, Burnet, Neil G., Calugaru, Valentin, Compter, Inge, Coremans, Ida E.M., Høyer, Morton, Lambrecht, Maarten, Nyström, Petra Witt, Méndez Romero, Alejandra, Paulsen, Frank, Perpar, Ana, de Ruysscher, Dirk, Renard, Laurette, Timmermann, Beate, Vitek, Pavel, Weber, Damien C., van der Weide, Hiske L., Whitfield, Gillian A., Wiggenraad, Ruud, and Troost, Esther G.C.
- Published
- 2018
- Full Text
- View/download PDF
13. Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma
- Author
-
Tensaouti, Fatima, Ducassou, Anne, Chaltiel, Léonor, Sevely, Annick, Bolle, Stéphanie, Padovani, Laetitia, Jouin, Anais, Alapetite, Claire, Supiot, Stéphane, Huchet, Aymeri, Bernier, Valérie, Claude, Line, Kerr, Christine, Le Prisé, Elisabeth, Bertozzi-Salamon, Anne-Isabelle, Liceaga, Samuel, Lotterie, Jean Albert, Péran, Patrice, and Laprie, Anne
- Published
- 2018
- Full Text
- View/download PDF
14. Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma
- Author
-
Tensaouti, Fatima, Ducassou, Anne, Chaltiel, Léonor, Bolle, Stéphanie, Muracciole, Xavier, Coche-Dequeant, Bernard, Alapetite, Claire, Bernier, Valérie, Claude, Line, Supiot, Stéphane, Huchet, Aymeri, Kerr, Christine, le Prisé, Elisabeth, and Laprie, Anne
- Published
- 2017
- Full Text
- View/download PDF
15. Deep-Learning for Rapid Estimation of the Out-of-Field Dose in External Beam Photon Radiation Therapy – A Proof of Concept.
- Author
-
Benzazon, Nathan, Carré, Alexandre, de Kermenguy, François, Niyoteka, Stéphane, Maury, Pauline, Colnot, Julie, M'hamdi, Meissane, Aichi, Mohammed El, Veres, Cristina, Allodji, Rodrigue, de Vathaire, Florent, Sarrut, David, Journy, Neige, Alapetite, Claire, Grégoire, Vincent, Deutsch, Eric, Diallo, Ibrahima, and Robert, Charlotte
- Subjects
- *
CONVOLUTIONAL neural networks , *EXTERNAL beam radiotherapy , *ROOT-mean-squares , *LINEAR accelerators , *CHILD patients , *IMMUNOTHERAPY - Abstract
The dose deposited outside of the treatment field during external photon beam radiation therapy treatment, also known as out-of-field dose, is the subject of extensive study as it may be associated with a higher risk of developing a second cancer and could have deleterious effects on the immune system that compromise the efficiency of combined radio-immunotherapy treatments. Out-of-field dose estimation tools developed today in research, including Monte Carlo simulations and analytical methods, are not suited to the requirements of clinical implementation because of their lack of versatility and their cumbersome application. We propose a proof of concept based on deep learning for out-of-field dose map estimation that addresses these limitations. For this purpose, a 3D U-Net, considering as inputs the in-field dose, as computed by the treatment planning system, and the patient's anatomy, was trained to predict out-of-field dose maps. The cohort used for learning and performance evaluation included 3151 pediatric patients from the FCCSS database, treated in 5 clinical centers, whose whole-body dose maps were previously estimated with an empirical analytical method. The test set, composed of 433 patients, was split into 5 subdata sets, each containing patients treated with devices unseen during the training phase. Root mean square deviation evaluated only on nonzero voxels located in the out-of-field areas was computed as performance metric. Root mean square deviations of 0.28 and 0.41 cGy/Gy were obtained for the training and validation data sets, respectively. Values of 0.27, 0.26, 0.28, 0.30, and 0.45 cGy/Gy were achieved for the 6 MV linear accelerator, 16 MV linear accelerator, Alcyon cobalt irradiator, Mobiletron cobalt irradiator, and betatron device test sets, respectively. This proof-of-concept approach using a convolutional neural network has demonstrated unprecedented generalizability for this task, although it remains limited, and brings us closer to an implementation compatible with clinical routine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. The Comet Assay as a Repair Test for Prenatal Diagnosis of Xeroderma Pigmentosum and Trichothiodystrophy.
- Author
-
Alapetite, Claire, Benoit, Annie, Moustacchi, Ethel, and Sarasin, Alain
- Subjects
- *
XERODERMA pigmentosum , *PHOTOSENSITIVITY disorders , *FIBROBLASTS , *NUCLEOTIDES , *DNA damage , *PRENATAL diagnosis - Abstract
Xeroderma pigmentosum (XP) and trichothiodystrophy (TTD) are autosomal recessive diseases associated with extreme cutaneous photosensitivity, a defect in nucleotide excision repair (NER), and genetic complexity. Severe prognosis and lack of treatment led families at risk to request genetic counseling. Unscheduled DNA synthesis (UDS) is the classic method for diagnosis and requires 4 to 5 wk before conclusion. The use of the alkaline comet assay (single cell gel electrophoresis assay) is proposed as a simple repair test for earlier prenatal diagnosis. Amniotic or chorionic villus cells in two pregnancies at risk for XP and one for TTD were examined in comparison with skin fibroblasts of family members or with repair-proficient or -deficient control cells. The comet assay and the UDS test were performed in parallel. In repair-proficient cells, DNA strand breaks due to the incision of UV-induced DNA damage result in increased migration of high molecular weight DNA in the comet assay. Fetal cells demonstrate repair capacity similar to that of fibroblasts. Incision repair-deficient XP and TTD cells, after post-UV incubation, migration does not occur and comet moments are reduced. Two fetuses belonging to two XP families responded normally and were diagnosed as unaffected. Fetal cells in a TTD family had reduced comet moments and a low UDS. This fetus was diagnosed and confirmed later as affected. Heterozygotes had normal responses with both assays. The comet assay offers discrimination similar to that of the UDS assay in identifying NER-deficient phenotypes. Practical advantages in view of prenatal diagnosis include the reduced number of cells required, a 24-h delay in obtaining results, and no need for radioactivity. [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
17. Respective Roles of Surgery, Chemotherapy, and Radiation Therapy for Recurrent Pediatric and Adolescent Ependymoma: A National Multicentric Study.
- Author
-
Desrousseaux, Jacques, Claude, Line, Chaltiel, Leonor, Tensaouti, Fatima, Padovani, Laetitia, Bolle, Stephanie, Escande, Alexandre, Alapetite, Claire, Supiot, Stéphane, Bernier-Chastagner, Valérie, Huchet, Aymeri, Leseur, Julie, Truc, Gilles, Leblond, Pierre, Bertozzi, Anne-Isabelle, Ducassou, Anne, and Laprie, Anne
- Subjects
- *
PEDIATRIC therapy , *RADIOTHERAPY , *EPENDYMOMA , *TEENAGERS , *SURGERY , *CANCER chemotherapy - Abstract
Half of the children and adolescents treated for intracranial ependymoma experience recurrences that are not managed in a standardized manner. This study aimed to retrospectively evaluate recurrence treatments. We assessed overall survival (OS) and progression-free survival (PFS) after a first relapse in a population of patients from the Pediatric Ependymoma Photons Protons and Imaging study (PEPPI study) who were treated with surgery and radiation therapy in French Society of Childhood Cancer reference centers between 2000 and 2013. Data were analyzed using the Cox model as well as a landmark analysis at 4 months that accounted for the guarantee-time bias. The median follow-up of the whole population of 202 patients was 105.1 months, with a 10-year OS of 68.2% and PFS of 45.5%. Among the 100 relapse cases, 68.0% were local relapses, 20.0% were metastatic, and 12.0% were combined (local and metastatic). Relapses were treated by surgery (n = 79) and/or reirradiation (n = 52) and/or chemotherapy (n = 22). The median follow-up after relapse was 77.8 months. The OS and PFS at 5 years were 43.1% and 16.2%, respectively. After surgery or radiation therapy of the first relapse, OS and PFS were more favorable, whereas treatments that included chemotherapy with or without focal treatment were associated with worse OS and PFS. In the multivariate analysis, stereotactic hypofractionated reirradiation after surgery was associated with a significantly better outcome (OS, P =.030; PFS, P =.008) and chemotherapy with a worse outcome (OS, P =.028; PFS, P =.033). This analysis of relapse treatments within the PEPPI study determined that irrespective of whether the relapse was localized or metastatic, treatments that included surgery and/or reirradiation had better outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
18. Proton beam therapy for skull base chordomas in 106 patients: A dose adaptive radiation protocol.
- Author
-
Calugaru, Valentin, Mammar, Hamid, Alapetite, Claire, De Marzi, Ludovic, Dendale, Rémi, Fung, Vivien, Feuvret, Loïc, Bolle, Stéphanie, Maingon, Philippe, Froelich, Sébastien, Habrand, Jean-Louis, and Noël, Georges
- Subjects
- *
CHORDOMA , *DOSE-response relationship (Radiation) , *PROTON therapy , *SKULL base , *TREATMENT effectiveness - Abstract
Background and purpose To evaluate clinical results and safety of a dose adaptive protocol based on tumor volume coverage and critical structure constraints, for the treatment of skull base chordomas. Material and methods Between May 2006 and October 2012, 106 patients with skull base chordoma were treated by combined photon and proton irradiation. Prescribed dose levels were 68.4, 70.2, 72 and 73.8 Gy(RBE) in once daily fractionation of 1.8 Gy(RBE). Dose level and dosimetric constraints to organs at risk depended on postoperative residual Gross Tumor Volume (GTV) coverage. Local control (LC) and overall survival (OS) were evaluated using the Kaplan–Meier method. Results With a median follow-up of 61 months, the 2-year, 4-year, and 5-year LC rates were 88.6%, 78.3%, and 75.1%, respectively. GTV > 25 mL ( p = 0.034 , HR = 2.22; 95%CI 1.06–4.62) was an independent unfavorable prognostic factor of LC. The 2-year, 4-year, and 5-year OS rates were 99%, 90.2%, and 88.3%, respectively. Grade 3–5 late toxicity was observed in 7 patients, resulting in 93% 5-year freedom from high-grade toxicity. Conclusions This study suggests that the probability of LC of skull base chordomas depends on postoperative GTV. The dose adaptive protocol achieves acceptable local control. Future studies should investigate whether further dose escalation to doses in excess of 74 Gy(RBE) would achieve better results. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Inhibin B and Antimüllerian Hormone as Markers of Gonadal Function after Treatment for Medulloblastoma or Posterior Fossa Ependymoma during Childhood.
- Author
-
Cuny, Ariane, Trivin, Christine, Brailly-Tabard, Sylvie, Adan, Luis, Zerah, Michel, Sainte-Rose, Christian, Alapetite, Claire, Brugières, Laurence, Habrand, Jean-Louis, Doz, François, and Brauner, Raja
- Abstract
Objective: To evaluate the roles of hypothalamic-pituitary and spinal irradiations and chemotherapy in gonadal deficiency after treatment for medulloblastoma or posterior fossa ependymoma by measuring levels of plasma inhibin B and antimüllerian hormone (AMH). Study design: A total of 34 boys and 22 girls were classified as having normal levels of plasma follicle-stimulating hormone (FSH; <9 IU/L), or abnormal levels of FSH (>9 IU/L) and luteinizing hormone (LH; <5 or >5 IUL). Results: Two boys had partial gonadotropin deficiency, combined with testicular deficiency in one boy. Six boys had increased levels of FSH, indicating tubular deficiency, combined with Leydig cell deficiency in 5 boys. The 7 boys with inhibin B levels <100 ng/mL included the one with combined deficiencies and the 6 with testicular deficiency. Puberty did not progress in 7 girls; 3 had gonadotropin deficiency, combined with ovarian deficiency in one, and 4 had increased FSH levels, indicating ovarian deficiency. Inhibin B and AMH levels were low in the girl with combined deficiencies, in the 4 girls with ovarian deficiency, and in 4 girls with normal clinical-biological ovarian function, including 2 who underwent ovarian transposition before irradiation. Conclusion: The plasma concentrations of inhibin B and AMH are useful means of detecting primary gonad deficiency in patients with no increase in their plasma gonadotropin levels because of radiation-induced gonadotropin deficiency. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
20. Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group.
- Author
-
Morana, Giovanni, Shaw, Dennis, MacDonald, Shannon M, Alapetite, Claire, Ajithkumar, Thankamma, Bhatia, Aashim, Brisse, Hervé, Jaimes, Camilo, Czech, Thomas, Dhall, Girish, Fangusaro, Jason, Faure-Conter, Cecile, Fouladi, Maryam, Hargrave, Darren, Harreld, Julie H, Mitra, Dipayan, Nicholson, James C, Souweidane, Mark, Timmermann, Beate, and Calaminus, Gabriele
- Subjects
- *
PEDIATRIC oncology , *GERM cells , *BRAIN tumors , *AMERICANS , *TUMORS , *ONCOLOGY , *BRAIN tumor treatment , *GERM cell tumors , *CONSENSUS (Social sciences) , *DIAGNOSTIC imaging , *TREATMENT effectiveness , *NORTH Americans ,CENTRAL nervous system tumors - Abstract
Homogeneous and common objective disease assessments and standardised response criteria are important for better international clinical trials for CNS germ cell tumours. Currently, European protocols differ from those of North America (the USA and Canada) in terms of criteria to assess radiological disease response. An international working group of the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group was therefore established to review existing literature and current practices, identify major challenges regarding imaging assessment, and develop consensus recommendations for imaging response assessment for patients with CNS germ cell tumours. New clinical imaging standards were defined for the most common sites of CNS germ cell tumour and for the definition of locoregional extension. These new standards will allow the evaluation of response to therapy in patients with CNS germ cell tumours to be more consistent, and facilitate direct comparison of treatment outcomes across international studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Inoperable scalp cutaneous angiosarcoma: Complete response after definitive external beam radiation therapy - brachytherapy association.
- Author
-
Le Roy, Charlotte, Le Péchoux, Cécile, Alapetite, Claire, Bahleda, Ratislav, Ngo, Carine, Honoré, Charles, Faron, Matthieu, Le Cesne, Axel, Mir, Olivier, Haie-Meder, Christine, Chargari, Cyrus, and Levy, Antonin
- Subjects
- *
EXTERNAL beam radiotherapy , *RADIOISOTOPE brachytherapy , *ANGIOSARCOMA , *SCALP , *INTENSITY modulated radiotherapy , *SKIN tumors , *RADIATION doses , *RADIOTHERAPY , *SARCOMA - Abstract
Effective treatments are scarce in non-operable scalp cutaneous angiosarcoma patients. Curative-intent definitive sequential IMRT and plesiobrachytherapy allowed complete response with limited side effect in two elder patients. This could represent a non-invasive therapeutic option for patients with locally advanced presentation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. Proton Therapy in Pediatric Skull Base and Cervical Canal Low-Grade Bone Malignancies
- Author
-
Habrand, Jean-Louis, Schneider, Ralf, Alapetite, Claire, Feuvret, Loic, Petras, Slavo, Datchary, Jean, Grill, Jacques, Noel, Georges, Helfre, Sylvie, Ferrand, Regis, Bolle, Stephanie, and Sainte-Rose, Christian
- Subjects
- *
BONE cancer , *RADIOTHERAPY , *CHORDOMA , *NOTOCHORD cancer - Abstract
Purpose: To evaluate outcomes and tolerance of high-dose photon and proton therapy in the management of skull base and cervical canal primary bony malignancies in children. Patients and Methods: Thirty children were treated postoperatively with high-dose photon–proton (29 patients) or protons-only (1 patient) radiotherapy. Twenty-six patients had chordomas (CH), 3 had low-grade chondrosarcomas (CS), and 1 had an aggressive chondroma (AC). The mean age was 12.8 years. At the time of radiation, all but 1 patient had a gross residue. The anatomic sites affected were skull base (n = 16), cervical canal (n = 1), or both (n = 13). Mean total dose was 68.4 cobalt Gray equivalents, conventionally fractionated. Results: With a mean follow-up of 26.5 months, 5 of 30 children failed locally: 5 of 5 lesions were CH, 5 of 5 patients had experienced pain at presentation (p = 0.03), and 4 of 5 had cervical extension (p = 0.07). The 5-year overall survival/progression-free survival rates for CS and CH were 100%/100% and 81%/77%, respectively. Side effects were scored according to the National Cancer Institute Common Terminology Criteria for Adverse Events v3.0. Acute toxicity ranged between 0 and 2. Late toxicity of radiotherapy was severe in 1 patient (Grade 3 auditory) and minor or mild in the rest of the population (7 patients with Grade 2 pituitary dysfunction). Conclusions: High-dose combined fractionated photon–proton therapy is well tolerated in children and allows excellent local control with minimal long-term toxicity. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
23. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
- Author
-
Carrie, Christian, Kieffer, Virginie, Figarella-Branger, Dominique, Masliah-Planchon, Julien, Bolle, Stéphanie, Bernier, Valérie, Laprie, Anne, Supiot, Stéphane, Leseur, Julie, Habrand, Jean-Louis, Alapetite, Claire, Kerr, Christine, Dufour, Christelle, Claude, Line, Chapet, Sophie, Huchet, Aymeri, Bondiau, Pierre-Yves, Escande, Alexandre, Truc, Gilles, and Nguyen, Tan Dat
- Subjects
- *
MEDULLOBLASTOMA , *RADIOTHERAPY , *PROGRESSION-free survival , *PROGNOSIS , *SURVIVAL analysis (Biometry) , *CEREBELLAR tumors , *PROTEINS , *RESEARCH , *ONCOGENES , *RESEARCH methodology , *GLIOMAS , *CANCER relapse , *COGNITION , *MEDICAL cooperation , *EVALUATION research , *BRAIN tumors , *COMPARATIVE studies , *INTELLECT , *QUALITY assurance , *GENE amplification , *CENTRAL nervous system , *LONGITUDINAL method - Abstract
Purpose: Medulloblastoma has recently been characterized as a heterogeneous disease with 4 distinct molecular subgroups: wingless (WNT), sonic hedgehog (SHH), group 3, and group 4, with a new definition of risk stratification. We report progression-free survival, overall survival, and long-term cognitive effects in children with standard-risk medulloblastoma exclusively treated with hyperfractionated radiation therapy (HFRT), reduced boost volume, and online quality control, and we explore the prognostic value of biological characteristics in this chemotherapy-naïve population.Methods and Materials: Patients with standard-risk medulloblastoma were enrolled in 2 successive prospective multicentric studies, MSFOP 98 and MSFOP 2007, and received exclusive HFRT (36 Gy, 1 Gy/fraction twice daily) to the craniospinal axis followed by a boost at 68 Gy restricted to the tumor bed (1.5 cm margin), with online quality assurance before treatment. Patients with MYC or MYCN amplification were not excluded at the time of the study. We report progression-free survival and overall survival in the global population, and according to molecular subgroups as per World Health Organization 2016 molecular classification, and we present cognitive evaluations based on the Wechsler scale.Results: Data from 114 patients included in the MSFOP 98 trial from December 1998 to October 2001 (n = 48) and in the MSFOP 2007 from October 2008 to July 2013 (n = 66) were analyzed. With a median follow-up of 16.2 (range, 6.4-19.6) years for the MSFOP 98 cohort and 6.5 (1.6-9.6) years for the MSFOP 2007 cohort, 5-year overall survival and progression-free survival in the global population were 84% (74%-89%) and 74% (65%-81%), respectively. Molecular classification was determined for 91 patients (WNT [n = 19], SHH [n = 12], and non-WNT/non-SHH [n = 60]-including group 3 [n = 9], group 4 [n = 29], and not specified [n = 22]). Our results showed more favorable outcome for the WNT-activated subgroup and a worse prognosis for SHH-activated patients. Three patients had isolated extra-central nervous system relapse. The slope of neurocognitive decline in the global population was shallower than that observed in patients with a normofractionated regimen combined with chemotherapy.Conclusions: HFRT led to a 5-year survival rate similar to other treatments combined with chemotherapy, with a reduced treatment duration of only 6 weeks. We confirm the MSFOP 98 results and the prognostic value of molecular status in patients with medulloblastoma, even in the absence of chemotherapy. Intelligence quotient was more preserved in children with medulloblastoma who received exclusive HFRT and reduced local boost, and intelligence quotient decline was delayed compared with patients receiving standard regimen. HFRT may be appropriate for patients who do not consent to or are not eligible for prospective clinical trials; for patients from developing countries for whom aplasia or ileus may be difficult to manage in a context of high cost/effectiveness constraints; and for whom shortened duration of RT may be easier to implement. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
24. Relapsing intracranial germ cell tumours warrant retreatment.
- Author
-
Callec, Laetitia, Lardy-Cleaud, Audrey, Guerrini-Rousseau, Lea, Alapetite, Claire, Vignon, Laure, Chastagner, Pascal, Frappaz, Didier, and Faure-Conter, Cecile
- Subjects
- *
ANTINEOPLASTIC agents , *BRAIN tumors , *ADJUVANT treatment of cancer , *CANCER chemotherapy , *CANCER relapse , *CONFIDENCE intervals , *DOSE-effect relationship in pharmacology , *MEDICAL records , *SURVIVAL , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DESCRIPTIVE statistics , *GERMINOMA , *ACQUISITION of data methodology , *CHEMORADIOTHERAPY - Abstract
The optimal therapeutic strategy for relapsing intracranial germ cell tumours (IGCTs) has not been clearly established. Relapses of IGCTs, occurring from 01/01/1990 to 31/12/2014, were retrieved from the Societe Française d'Oncologie Pediatrique-TGM 90, 92 and GCT 96 protocols, and from the National Childhood Solid Tumour Registry. Refractory IGCTs were excluded. Forty-four relapsing IGCTs were identified: 14 were initially treated for histologically proven germinomas (germinoma group), 5 for non-histologically proven germinomas (putative germinoma group) and 25 for non-germinomatous germ cell tumours (NGGCTs) (NGGCT group). In the germinoma group, the 5-year event-free survival (EFS) and overall survival (OS) were 79% (95% confidence interval [CI]: 47–93) and 86% (95% CI: 54–96), respectively. Only one of the 11 patients treated with reirradiation experienced a further relapse. A trend of better EFS was observed for relapses at sites that were not initially involved: 5-year EFS of 100% versus 67% (95% CI: 28–88), p = 0.09. In the putative germinoma group, 4 of 5 patients experienced a further event, leading to 2 deaths. In the NGGCT group, the 5-year EFS and OS were 56% (95% CI: 35–73) and 60% (95% CI: 38–76), respectively. A significant improvement in outcomes after high-dose chemotherapy (HDC) was observed: 5-year OS of 72% (95% CI: 46–87) versus 29% (95% CI: 4–61), p = 0.006. Relapsing germinomas are highly curable; reirradiation appears to play a key role. Histological proof at initial diagnosis if markers are negative is crucial. Despite inferior outcomes relapsing, NGGCTs can be cured in a significant proportion of cases provided intensive treatment including HDC is applied. • Histology at diagnosis and at relapse has an impact on prognosis. • Relapsing germinomas are highly curable; reirradiation appears to play a key role. • In this group, high-dose chemotherapy (HDC) with reirradiation may be overtreatment. • Recurrent non-germinomatous germ cell tumours have a less favourable prognosis. • In this group, both HDC and reirradiation are required for cure. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. A rapid review of evidence and recommendations from the SIOPE radiation oncology working group to help mitigate for reduced paediatric radiotherapy capacity during the COVID-19 pandemic or other crises.
- Author
-
Janssens, Geert O., Mandeville, Henry C., Timmermann, Beate, Maduro, John H., Alapetite, Claire, Padovani, Laetitia, Horan, Gail, Lassen-Ramshad, Yasmin, Dieckmann, Karin, Ruebe, Christian, Thorp, Nicky, Gandola, Lorenza, Ajithkumar, Thankamma, and Boterberg, Tom
- Subjects
- *
COVID-19 pandemic , *MIDDLE-income countries , *LOW-income countries , *RADIOTHERAPY - Abstract
• No guidelines for the optimal use of paediatric radiotherapy facilities during a shortage. • Recommendations for the optimal use of paediatric radiotherapy facilities are presented. • This guideline has applications in low and middle income countries with limited resources. To derive evidence-based recommendations for the optimal utilisation of resources during unexpected shortage of radiotherapy capacity. We have undertaken a rapid review of published literature on the role of radiotherapy in the multimodality treatment of paediatric cancers governing the European practise of paediatric radiotherapy. The derived data has been discussed with expert paediatric radiation oncologists to derive a hierarchy of recommendations. The general recommendations to mitigate the potential detriment of an unexpected shortage of radiotherapy facilities include: (1) maintain current standards of care as long as possible (2) refer to another specialist paediatric radiotherapy department with similar level of expertise (3) prioritise use of existing radiotherapy resources to treat patients with tumours where radiotherapy has the most effect on clinical outcome (4) use chemotherapy to defer the start of radiotherapy where timing of radiotherapy is not expected to be detrimental (5) active surveillance for low-grade tumours if appropriate and (6) consider iso-effective hypofractionated radiotherapy regimens only for selected patients with predicted poor prognosis. The effectiveness of radiotherapy and recommendations for prioritisation of its use for common and challenging paediatric tumours are discussed. This review provides evidence-based treatment recommendations during unexpected shortage of paediatric radiotherapy facilities. It has wider applications for the optimal utilisation of facilities, to improve clinical outcome in low- and middle-income countries, where limited resources continue to be a challenge. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
26. Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group.
- Author
-
Hoeben, Bianca A, Carrie, Christian, Timmermann, Beate, Mandeville, Henry C, Gandola, Lorenza, Dieckmann, Karin, Ramos Albiac, Monica, Magelssen, Henriette, Lassen-Ramshad, Yasmin, Ondrová, Barbora, Ajithkumar, Thankamma, Alapetite, Claire, Balgobind, Brian V, Bolle, Stephanie, Cameron, Alison L, Davila Fajardo, Raquel, Dietzsch, Stefan, Dumont Lecomte, Delphine, van den Heuvel-Eibrink, Marry M, and Kortmann, Rolf D
- Subjects
- *
ONCOLOGY , *PEDIATRICS , *RADIATION doses , *RADIOTHERAPY , *TUMORS - Abstract
Inhomogeneities in radiotherapy dose distributions covering the vertebrae in children can produce long-term spinal problems, including kyphosis, lordosis, scoliosis, and hypoplasia. In the published literature, many often interrelated variables have been reported to affect the extent of potential radiotherapy damage to the spine. Articles published in the 2D and 3D radiotherapy era instructed radiation oncologists to avoid dose inhomogeneity over growing vertebrae. However, in the present era of highly conformal radiotherapy, steep dose gradients over at-risk structures can be generated and thus less harm is caused to patients. In this report, paediatric radiation oncologists from leading centres in 11 European countries have produced recommendations on how to approach dose coverage for target volumes that are adjacent to vertebrae to minimise the risk of long-term spinal problems. Based on available information, it is advised that homogeneous vertebral radiotherapy doses should be delivered in children who have not yet finished the pubertal growth spurt. If dose fall-off within vertebrae cannot be avoided, acceptable dose gradients for different age groups are detailed here. Vertebral delineation should include all primary ossification centres and growth plates, and therefore include at least the vertebral body and arch. For partial spinal radiotherapy, the number of irradiated vertebrae should be restricted as much as achievable, particularly at the thoracic level in young children (<6 years old). There is a need for multicentre research on vertebral radiotherapy dose distributions for children, but until more valid data become available, these recommendations can provide a basis for daily practice for radiation oncologists who have patients that require vertebral radiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
27. Pediatric Localized Intracranial Ependymomas: A Multicenter Analysis of the Société Française de lutte contre les Cancers de l'Enfant (SFCE) from 2000 to 2013.
- Author
-
Ducassou, Anne, Padovani, Laetitia, Chaltiel, Leonor, Bolle, Stéphanie, Habrand, Jean-Louis, Claude, Line, Carrie, Christian, Muracciole, Xavier, Coche-Dequeant, Bernard, Alapetite, Claire, Supiot, Stéphane, Demoor-Goldschmidt, Charlotte, Bernier-Chastagner, Valerie, Huchet, Aymeri, Leseur, Julie, Le Prise, Elisabeth, Kerr, Christine, Truc, Gilles, Nguyen, Tan Dat, and Bertozzi, Anne-Isabelle
- Subjects
- *
INTRACRANIAL tumors , *EPENDYMOMA , *CANCER radiotherapy , *FOLLOW-up studies (Medicine) , *CANCER patients , *DISEASE relapse , *TUMOR treatment , *BRAIN tumors , *COMPARATIVE studies , *GLIOMAS , *RESEARCH methodology , *MEDICAL cooperation , *PROGNOSIS , *RADIATION doses , *RESEARCH , *EVALUATION research ,BRAIN tumor diagnosis - Abstract
Purpose: The objective of this study was to analyze survival and prognostic factors for children, adolescents, and young adults treated with postoperative radiation therapy (RT) for intracranial ependymoma.Methods and Materials: Between 2000 and 2013, 202 patients aged ≤25 years were treated in the 13 main French pediatric RT reference centers. Their medical records were reviewed for information, treatments received, and survival rates. All children had received postoperative RT- conformal, intensity modulated, or proton beam. In 2009, the prescribed standard dose in France rose from 54 Gy to 59.4 Gy.Results: Median follow-up was 53.8 months (95% confidence interval [CI] 47-63.5). Median age at RT was 5 years (range 1-22), and 32% of the children treated were aged <3 years. Regarding treatment, 85.6% of patients underwent gross total resection, 62% of patients received conformal RT (vs 29% for intensity modulated RT and 8% for proton beam RT), 62.4% of patients received a dose >54 Gy, and 71% received chemotherapy. Of the 84 relapses, 75% were local. The cumulative incidence of local relapse was 24.4% (95% CI 18.2-31.2) at 3 years and 31.3% (95% CI 24-38.9) at 5 years. The 5-year disease-free survival (DFS) and overall survival rates were 50.4% (95% CI 42.2-58) and 71.4% (95% CI 63.1-78.2). Tumor grade was the only prognostic factor for local relapse and DFS. Tumor grade, age, and extent of resection were independent prognostic factors for overall survival.Conclusions: We confirmed several clinical and tumoral prognostic factors in a large French multicenter study. DFS for intracranial ependymoma remains low, and new biological and imaging markers are needed to distinguish among different subtypes, adapt treatments, and improve survival. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
28. Hippocampal Sparing During Craniospinal Irradiation: What Did We Learn About the Incidence of Perihippocampus Metastases?
- Author
-
Padovani, Laetitia, Chapon, Frédérique, André, Nicolas, Boucekine, Mohamed, Geoffray, Anne, Bourdeau, Franck, Masliah-Planchon, Julien, Claude, Line, Huchet, Aymeri, Laprie, Anne, Supiot, Stephane, Coche-Dequéant, Bernard, Kerr, Christine, Alapetite, Claire, Leseur, Julie, Nguyen, Tandat, Chapet, Sophie, Bernier, Valerie, Bondiau, Pierre-Yves, and Noel, Georges
- Subjects
- *
IRRADIATION , *METASTASIS , *MEDULLOBLASTOMA , *RADIOTHERAPY , *TISSUE wounds , *BRAIN tumors , *CENTRAL nervous system , *GLIOMAS , *HIPPOCAMPUS (Brain) , *MAGNETIC resonance imaging , *SURVIVAL , *THERAPEUTICS , *RETROSPECTIVE studies - Abstract
Purpose: To identify the incidence of patients with perihippocampal metastases to assess the risk of brain relapse when sparing the hippocampal area. Medulloblastoma (MB) represents 20% of pediatric brain tumors. For high-risk MB patients, the 3- to 5-year event-free survival rate has recently improved from 50% to >76%. Many survivors, however, experience neurocognitive side effects. Several retrospective studies of patients receiving whole brain irradiation (WBI) have suggested a relationship between the radiation dose to the hippocampus and neurocognitive decline. The hippocampal avoidance-WBI (HA-WBI) approach could partially reduce neurocognitive impairment in children treated for high-risk MB.Methods and Materials: From 2008 to 2011, 51 patients with high-risk MB were treated according to the French trial primitive neuroectodermal tumor HR+5. Hippocampal contouring was manually generated on 3-dimensional magnetic resonance images according to the Radiation Therapy Oncology Group 0933 atlas. The distribution of metastases was assessed relative to the hippocampus: 0 to 5 mm for the first perihippocampal area and 5 to 15 mm for the rest of the perihippocampal area.Results: The median patient age was 8.79 years (33% female). After a follow-up of 2.4 years, 43 patients were alive; 28 had had brain metastasis at diagnosis and 2 at relapse, with 16% in the first perihippocampal area and 43% in the rest of the perihippocampal area. Of the 18 patients without brain metastases at diagnosis, including M1 patients, none developed secondary lesions within the first or the rest of the perihippocampal area, after receiving 36 Gy. No clinical or biological factor was significantly associated with the development of perihippocampal metastases.Conclusions: Our results suggest the HA-WBI strategy should be evaluated for the subgroup of high-risk MB patients without metastatic disease. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
29. Combined Proton and Photon Conformal Radiotherapy for Intracranial Atypical and Malignant Meningioma
- Author
-
Boskos, Christos, Feuvret, Loic, Noel, Georges, Habrand, Jean-Louis, Pommier, Pascal, Alapetite, Claire, Mammar, Hamid, Ferrand, Regis, Boisserie, Gilbert, and Mazeron, Jean-Jacques
- Subjects
- *
CANCER radiotherapy , *PHOTON beams , *PROTON therapy , *MENINGIOMA , *TREATMENT effectiveness , *RETROSPECTIVE studies , *BIOCOMPATIBILITY , *THERAPEUTICS ,CANCER histopathology - Abstract
Purpose: To evaluate retrospectively the efficacy of conformal fractionated radiotherapy combining proton and photon beams after primary surgery for treatment of atypical and malignant meningiomas. Patients and Methods: Between September 1999 and October 2006, 24 patients (12 male, 12 female) with histopathologically proven meningioma (atypical 19, malignant 5) received postoperative combined radiotherapy with a 201-MeV proton beam at the Centre Protontherapie d''Orsay and a high-energy photon beam. Six patients underwent gross total resection and 18 a subtotal resection. Median gross tumor volume and clinical target volume were 44.7 cm3 and 153.3 cm3, respectively. Mean total irradiation dose was 65.01 CGE (cobalt gray equivalent), with a mean proton total dose of 34.05 CGE and a mean photon total dose 30.96 CGE. Results: The median (range) follow-up interval was 32.2 (1–72) months. The overall mean local relapse-free interval was 27.2 (10–50) months, 28.3 (10–50) months for atypical meningioma and 23 (13–33) months for malignant meningioma. Ten tumors recurred locally. One-, 2-, 3-, 4-, 5-, and 8- year local control rates for the entire group of patients were 82.9% ± 7.8%, 82.9% ± 7.8%, 61.3% ± 11%, 61.3% ± 11%, 46.7% ± 12.3%, and 46.7% ± 12.3%, respectively. One-, 2-, 3-, 4-, 5-, and 8- year overall survival rates were 100%, 95.5% ± 4.4%, 80.4% ± 8.8%, 65.3% ± 10.6%, 53.2% ± 11.6%, and 42.6% ± 13%, respectively. Survival was significantly associated with total dose. There was no acute morbidity of radiotherapy. One patient developed radiation necrosis 16 months after treatment. Conclusions: Postoperative combination of conformal radiotherapy with protons and photons for atypical and malignant meningiomas is a well-tolerated treatment producing long-term tumor stabilization. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
30. A Treatment Planning Comparison of Combined Photon–Proton Beams Versus Proton Beams–Only for the Treatment of Skull Base Tumors
- Author
-
Feuvret, Loïc, Noel, Georges, Weber, Damien C., Pommier, Pascal, Ferrand, Regis, De Marzi, Ludovic, Dhermain, Frederic, Alapetite, Claire, Mammar, Hamid, Boisserie, Gilbert, Habrand, Jean-Louis, and Mazeron, Jean-Jacques
- Subjects
- *
SKULL diseases , *SKULL base , *CYSTS (Pathology) , *MEDICAL research - Abstract
Purpose: To compare treatment planning between combined photon–proton planning (CP) and proton planning (PP) for skull base tumors, so as to assess the potential limitations of CP for these tumors. Methods and Materials: Plans for 10 patients were computed for both CP and PP. Prescribed dose was 67 cobalt Gray equivalent (CGE) for PP; 45 Gy (photons) and 22 CGE (protons) for CP. Dose–volume histograms (DVHs) were calculated for gross target volume (GTV), clinical target volume (CTV), normal tissues (NT), and organs at risk (OARs) for each plan. Results were analyzed using DVH parameters, inhomogeneity coefficient (IC), and conformity index (CI). Results: Mean doses delivered to the GTVs and CTVs with CP (65.0 and 61.7 CGE) and PP (65.3 and 62.2 Gy CGE) were not significantly different (p > 0.1 and p = 0.72). However, the dose inhomogeneity was drastically increased with CP, with a mean significant incremental IC value of 10.5% and CP of 6.8%, for both the GTV (p = 0.01) and CTV (p = 0.04), respectively. The CI80% values for the GTV and CTV were significantly higher with PP compared with CP. Compared with CP, the use of protons only led to a significant reduction of NT and OAR irradiation, in the intermediate-to-low dose (≤80% isodose line) range. Conclusions: These results suggest that the use of CP results in levels of target dose conformation similar to those with PP. Use of PP significantly reduced the tumor dose inhomogeneity and the delivered intermediate-to-low dose to NT and OARs, leading us to conclude that this treatment is mainly appropriate for tumors in children. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
31. Common Strategy for Adult and Pediatric Medulloblastoma: A Multicenter Series of 253 Adults
- Author
-
Padovani, Laetitia, Sunyach, Marie-Pierre, Perol, David, Mercier, Cedric, Alapetite, Claire, Haie-Meder, Christine, Hoffstetter, Sylvette, Muracciole, Xavier, Kerr, Christine, Wagner, Jean-Philippe, Lagrange, Jean-Léon, Maire, Jean-Philippe, Cowen, Didier, Frappaz, Didier, and Carrie, Christian
- Subjects
- *
MEDULLOBLASTOMA , *CANCER in infants , *CANCER radiotherapy , *CLINICAL trials - Abstract
Purpose: To assess prognostic factors for adults with medulloblastoma in a multicenter, retrospective study. Methods and Materials: Data were collected by file review or mail inquiry for 253 adults treated between 1975 to 2004. Radiologists or surgeons assessed disease characteristics, such as volume and extension. Patients were classified as having either high- or standard-risk disease. Prognostic factors were analyzed. Results: Median patient age was 29 years. Median follow-up was 7 years. Radiotherapy was delivered in 246 patients and radiochemotherapy in 142. Seventy-four patients relapsed. Respective 5- and 10-year overall survival rates were 72% and 55%. Univariate analysis showed that survival significantly correlated with metastasis, postsurgical performance status, brainstem involvement, involvement of the floor of the fourth ventricle (V4), and radiation dose to the spine and to the posterior cerebral fossa (PCF). By multivariate analysis, brainstem, V4 involvement, and dose to the PCF were negative prognostic factors. In the standard-risk subgroup there was no overall survival difference between patients treated with axial doses of ≥34 Gy and patients treated with craniospinal doses <34 Gy plus chemotherapy. Conclusion: We report the largest series of medulloblastoma in adults. Prognostic factors were similar to those observed in children. Results suggest that patients with standard-risk disease could be treated with radiochemotherapy, reducing doses to the craniospinal area, maintaining at least 50 Gy to the PCF. The role of chemotherapy for this group is still unclear. A randomized study should be performed to confirm these results, but because frequency is very low, such a study would be difficult. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
32. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: Results of the French M-SFOP 98 protocol
- Author
-
Carrie, Christian, Muracciole, Xavier, Gomez, Frédéric, Habrand, Jean-Louis, Benhassel, Mohamed, Mege, Martine, Mahé, Marc, Quetin, Philippe, Maire, Jean Philippe, Soum, Françoise, Baron, Marie Helene, Clavere, Pierre, Chapet, Sophie, Gaci, Zineb, Kolodie, Helene, Maingon, Philippe, Vie, Bernard, Bernier, Valérie, Alapetite, Claire, and Hoffstetter, Sylvette
- Subjects
- *
HOSPITAL radiological services , *RADIOTHERAPY , *DRUGS , *MEDICAL radiology - Abstract
Purpose: Between December 1998 and October 2001, patients <19 years old were treated for standard-risk medulloblastoma according to the Medulloblastome-Société Française d’Oncologie Pédiatrique 1998 (M-SFOP 98) protocol. Patients received hyperfractionated radiotherapy (36 Gy in 36 fractions) to the craniospinal axis, a boost with conformal therapy restricted to the tumor bed (to a total dose of 68 Gy in 68 fractions), and no chemotherapy. Records of craniospinal irradiation were reviewed before treatment start. Results: A total of 48 patients were considered assessable. With a median follow-up of 45.7 months, the overall survival and progression-free survival rate at 3 years was 89% and 81%, respectively. Fourteen major deviations were detected and eight were corrected. No relapses occurred in the frontal region and none occurred in the posterior fossa outside the boost volume. Nine patients were available for volume calculation without reduction of the volume irradiated. We observed a reduction in the subtentorial volume irradiated to >60 Gy, but a slight increase in the volume irradiated to 40 Gy. No decrease in intelligence was observed in the 22 children tested during the first 2 years. Conclusion: This hyperfractionated radiotherapy protocol with a reduced boost volume and without chemotherapy was not associated with early relapses in children. Moreover, intellectual function seemed to be preserved. These results are promising. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
33. Basal Ganglia Germinoma in an Adult.
- Author
-
Vialatte de Pémille, Clément, Bielle, Franck, Mokhtari, Karima, Kerboua, Esma, Alapetite, Claire, and Idbaih, Ahmed
- Subjects
- *
BASAL ganglia , *GERMINOMA , *BRAIN cancer , *DYKE-Davidoff-Masson syndrome , *CENTRAL nervous system - Abstract
Intracranial germinoma is a rare primary brain cancer, usually located within the midline and mainly affecting Asian pediatric patients. Interestingly, we report here the peculiar case of a young North-African adult patient suffering from a basal ganglia germinoma without the classical ipsilateral cerebral hemiatrophy associated with this location. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.